Company intelligence / Profile preview

TR Korea

Seoul, Seoul, South Koreadnb.com ↗

Ownership: Private
Employees: ~82
Development stage: Commercial

Overview

T&R Biofab has commercialized bioresorbable medical devices and bioinks. The company actively researches artificial mini-organs ("organoids") and cell-based therapeutics using proprietary bioprinting technologies. Some products are already on the market; more advanced programs are in preclinical/R&D stages. No specific clinical trial results were found in the provided sources. The company positions itself as a leader in next-generation regenerative medicine platforms.

Therapeutic areas: Other
Modalities: Bioresorbable medical device (Biologic/Device)Bioink (Biologic/Device)Cell therapy (for organoids and cell therapeutics)3D bioprinting technology platform (enabling multiple modalities)
Industry: Biotech

Beyond the preview

Go deeper on TR Korea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TR Korea.

Explore the full profile